Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 16/20 | 0.59 |
| ▸ | SLC5A1 | P13866 | 9/20 | 0.59 |
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29408422 | 1.00 | SLC5A2 (0.59) | SLC5A2SLC5A1PDE2APDE10AHRH3 | |
| SCHEMBL1647749 | 1.00 | SLC5A2 (0.59) | SLC5A2SLC5A1PDE2APDE10AHRH3 | |
| SCHEMBL29408423 | 1.00 | SLC5A2 (0.59) | SLC5A2SLC5A1PDE2APDE10AHRH3 | |
| SCHEMBL29408425 | 1.00 | SLC5A2 (0.59) | SLC5A2SLC5A1PDE2APDE10AHRH3 | |
| SCHEMBL1647750 | 1.00 | SLC5A2 (0.59) | SLC5A2SLC5A1PDE2APDE10AHRH3 | |
| SCHEMBL2637466 | 0.93 | SLC5A2 (0.51) | SLC5A2SLC5A1HRH3 | |
| SCHEMBL30830341 | 0.88 | SLC5A2 (0.61) | SLC5A2SLC5A1PDE2APDE10AHRH3 | |
| SCHEMBL28411163 | 0.87 | SLC5A2 (0.49) | SLC5A2SLC5A1PDE2APDE10AHRH3 | |
| SCHEMBL28411159 | 0.87 | SLC5A2 (0.49) | SLC5A2SLC5A1PDE2APDE10AHRH3 | |
| SCHEMBL19189964 | 0.87 | SLC5A2 (0.60) | SLC5A2SLC5A1PDE2APDE10AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | claimed |
| CN-111265512-A | Composition containing a mixture of benzyl benzene derivatives and uses thereof | 黄泳华 | 2020-06-12 | — | — | CN | claimed |
| EP-1881990-B1 | PROCESSES FOR PREPARING OF GLUCOPYRANOSYL-SUBSTITUTED BENZYL-BENZENE DERIVATIVES AND INTERMEDIATES THEREIN | BOEHRINGER INGELHEIM INT (DE) | 2016-02-17 | — | — | EP | claimed |
| US-9127034-B2 | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivates and intermediates therein | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-08 | — | — | US | claimed |
| US-20100240879-A1 | PROCESSES FOR PREPARING OF GLUCOPYRANOSYL-SUBSTITUTED BENZYL-BENZENE DERIVATES AND INTERMEDIATES THEREIN | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | claimed |
| US-20060258749-A1 | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-16 | — | — | US | claimed |
| US-11046676-B2 | Process for preparation of empagliflozin or its co-crystals, solvates and their polymorphs thereof | LAURUS LABS LIMITED (IN) | 2021-06-29 | — | — | US | disclosed |
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | disclosed |
| CN-111265512-A | Composition containing a mixture of benzyl benzene derivatives and uses thereof | 黄泳华 | 2020-06-12 | — | — | CN | disclosed |
| US-20200131163-A1 | NOVEL PROCESS FOR PREPARATION OF EMPAGLIFLOZIN OR ITS CO-CRYSTALS, SOLVATES AND THEIR POLYMORPHS THEREOF | LAURUS LABS LIMITED (IN) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131163-A1 | NOVEL PROCESS FOR PREPARATION OF EMPAGLIFLOZIN OR ITS CO-CRYSTALS, SOLVATES AND THEIR POLYMORPHS THEREOF | SLC5A1, SLC5A2, DPP4 | SLC5A2 2/4885SLC5A1 1/4885PDE2A 1495/4885 |
| US-20060258749-A1 | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein | UGGT1, B3GAT3, B4GALT1 | SLC5A2 120/4885SLC5A1 111/4885PDE2A 3425/4885 |
| US-20100240879-A1 | PROCESSES FOR PREPARING OF GLUCOPYRANOSYL-SUBSTITUTED BENZYL-BENZENE DERIVATES AND INTERMEDIATES THEREIN | UGGT1, B3GAT3, B4GALT1 | SLC5A2 123/4885SLC5A1 85/4885PDE2A 3499/4885 |
| US-11046676-B2 | Process for preparation of empagliflozin or its co-crystals, solvates and their polymorphs thereof | SLC5A2, SLC5A1, DPP4 | SLC5A2 1/4885SLC5A1 2/4885PDE2A 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.